After griping for hours about President Trump’s upcoming speech on reducing prescription drug prices, you’d think I’d at least listen to the damn thing and then comment on it, wouldn’t you? I guess so. That would be the fair thing to do.
But here’s the thing: Sometimes I get tired of being sucked into long, dry analyses of Republican plans that we all know perfectly well are meaningless. Someone has to do it, and very often that someone is me. It’s my role in the vast politico-industrial complex, after all. But seriously, who cares? Trump himself barely understood what he was reading, and whatever it was, Congress is going to ignore it. Plus it’s Friday, and I’m tired. So fuck it.
Besides, there’s really no need for all that work. There are hundreds of analysts out there who know more than me about this stuff, and they render instant decisions on it via the stock market. So if all you want to know is whether Trump’s plan is good for consumers or good for pharmaceutical companies, just check out how pharmaceutical stocks did as Trump was delivering his speech. If stocks went down, that’s good news for consumers. If stocks went up, it’s good news for drug companies.
Can you guess which way pharmaceutical stocks went? Huh? Can you?
